China’s 15th Five-Year Plan: Implications for Drugs, Medical Devices, & Market Access 

On March 13, 2026, China adopted the “15th Five-Year Plan for National Economic and Social Development” (2026–2030). The plan sets national priorities for economic development, technology, social policy, and the environment, with important implications for innovative drugs, advanced medical devices, reimbursement, procurement, and China healthcare regulation. 

As the “15th Five-Year Plan” period begins, several healthcare-related measures have already moved into implementation. Together, they show how China is connecting innovation policy with regulatory pathways, reimbursement systems, centralized procurement, and healthcare delivery.  

At a Glance 

• China is shifting from the “14th Five-Year Plan” focus on breakthroughs toward implementation, application, and system integration. 
• Healthcare innovation remains a priority, with continued support for high-value and clinically relevant products.  
• Priority healthcare technologies include biomanufacturing, advanced therapies, brain-computer interfaces, and high-end medical devices. 
• Early reforms are already affecting regulatory pathways, reimbursement, centralized procurement, and primary care demand.  
• Market access is becoming more diversified, with public reimbursement, commercial insurance, and procurement reforms creating new routes for innovative products. 
• Overseas manufacturers should reassess China registration pathways, evidence strategy, reimbursement planning, and lifecycle compliance. 

How Five-Year Plans Drive Regulatory Change 

Five-Year Plans are top-level policy frameworks, not standalone binding regulations. Their influence comes from the way they guide legislative priorities, ministry-level implementation, funding decisions, and administrative reforms. 

For healthcare companies, this means the “15th Five-Year Plan” should be read as a directional document. It does not replace NMPA rules, reimbursement policies, or procurement requirements. Instead, it signals where regulatory authorities are likely to focus resources and where future implementation measures may emerge. 

The “15th Five-Year Plan” builds on earlier themes, including innovation-driven growth, healthcare system upgrading, and improved access to advanced therapies. What distinguishes this cycle is its stronger emphasis on system integration and real-world application. 

Within the broader national strategy, healthcare sits under the “Healthy China” framework. This places greater emphasis on: 

• Population health outcomes 
• Chronic disease management and aging-related care 
• Strengthening primary care and local healthcare delivery 
• Coordination between healthcare services, insurance, and pharmaceutical supply 

At the same time, the Plan is closely linked to broader priorities such as technological self-reliance and industrial upgrading.  

Implication for industry: Innovation continues to be encouraged, but it is increasingly evaluated based on clinical value, accessibility, and how well it fits within the healthcare system. 

From the 14th to the 15th Five-Year Plan 

The shift from the “14th Five-Year Plan” to the “15th Five-Year Plan” reflects a broader transition in China’s healthcare strategy. The previous cycle focused on building capacity and accelerating innovation. The new cycle places greater emphasis on system integration, local access, and commercialization of advanced technologies. 

The comparison below summarizes the main policy shifts relevant to innovative drugs, medical devices, reimbursement, procurement, and R&D planning: 

For foreign companies, the practical message is clear: policy is moving beyond enabling innovation toward ensuring that products move into clinical use, reimbursement pathways, and procurement systems. 

Early 2026 Measures Show How Policy Is Moving into Practice 

The first months of 2026 already show how the “15th Five-Year Plan” is being operationalized. Early measures connect the plan’s innovation priorities with concrete mechanisms for approval, reimbursement, procurement, and primary care delivery. 

Key measures implemented to date include: 

These policies form a consistent implementation pattern: stronger alignment between approval, pricing, reimbursement, procurement, healthcare delivery, and post-market utilization. 

Priority Sectors for Innovative Drugs and Medical Devices in China 

The “15th Five-Year Plan” identifies several high-impact sectors where regulatory support, funding, and accelerated pathways are likely to concentrate.  

Biomanufacturing and Advanced Therapies 

Biomanufacturing is one of the clearest healthcare priorities in the plan. China aims to strengthen capabilities across biological design, production, and application.  

For pharmaceutical companies, the strongest relevance lies in  

• Cell and gene therapies  
• Antibody drugs 
• Nucleic acid-based therapeutics 
• Radiopharmaceuticals 
• Vaccines and emergency-response medicines 

These areas reflect both innovation priorities and healthcare needs. 

Brain–Computer Interfaces and Neurotechnology 

Brain-computer interfaces are identified as a strategic emerging technology with direct healthcare applications. China is targeting BCI products for neurological disease diagnosis and treatment, motor rehabilitation, and health monitoring. 

The plan prioritizes: 

• New electrode systems 
• Specialized hardware and software chips 
• Signal encoding and decoding algorithms 
• Chinese-language corpus databases 

For medical device and digital health companies developing neurotechnology, implantable systems, rehabilitation devices, and data-driven monitoring tools, these priorities point to potential opportunities in China’s emerging BCI sector. Products with clear clinical value, strong technical validation, and China-relevant evidence are likely to be better positioned. 

High-End Medical Devices 

High-end medical devices remain a core policy focus. Priority product areas include advanced CT systems, high-resolution MRI, radiotherapy systems, intelligent surgical robots, and life-support systems. 

The plan also supports innovative implantable and interventional devices, particularly in neurostimulation, cardiovascular disease, and orthopedics. These categories are likely to remain important for both NMPA registration strategy and China market access planning, especially where products can demonstrate clear clinical value. 

Innovation Support Mechanisms 

China is combining sector priorities with targeted regulatory and policy tools designed to support innovation while maintaining control over access and cost.  

Key mechanisms include:  

• Defined exclusivity periods for selected products, including certain rare disease and pediatric drugs under updated regulatory frameworks  
• Strengthened early-resolution pathways for pharmaceutical patent disputes 
• Priority review and accelerated pathways for products addressing urgent clinical needs 
• Earlier regulatory engagement through formal communication channels during development 
• Continued optimization of clinical trial and review timelines 

Together, these measures are intended to improve predictability and support earlier alignment with regulators, particular for products with clinical value.  

China-Specific Evidence Will Matter More 

China’s R&D and regulatory agenda places increasing emphasis on  

• Domestic clinical research 
• Precision medicine 
• Population-specific data level  

For international companies, global clinical data remains important. However, its acceptance increasingly depends on demonstrating relevance to Chinese patient populations.  

In practice, this means: 

• Greater reliance on multi-regional clinical trials (MRCTs) that include China  
• Selective use of real-world evidence in defined regulatory or pilot settings 
• Stronger expectations for local clinical justification in both regulatory and market access discussions 

The implication is clear: China is not moving away from global data, but toward requiring clearer local relevance to support approval, reimbursement, and clinical adoption. 

Faster and More Flexible Review and Approval Pathways 

Regulatory efficiency is a central operational theme under the “15th Five-Year Plan.” Several 2026 measures address development burden, submission efficiency, and approval timelines. 

Key regulatory measures include: 

• Reduced batch and sample requirements for drug registration testing and import inspection 
• Full implementation of electronic submissions and certificates 
• Expanded acceptance of international multi-regional clinical trial (MRCT) data 
• Increased use of remote verification as a supplementary tool for overseas manufacturing site inspections under specific eligible scenarios 

At the same time, accelerated pathways remain targeted rather than universal, typically applying to products that demonstrate clear clinical importance or urgency. 

Expanding Reimbursement and Market Access Channels in China 

During the “15th Five-Year Plan” period, market access is increasingly shaped by how products move from approval into reimbursement, procurement, hospital listing, and clinical use. 

Public reimbursement and centralized procurement remain the main access routes. At the same time, policy support for commercial insurance is creating a complementary pathway for certain high-value products. 

Public Reimbursement and Commercial Insurance Are Developing in Parallel 

The 2025 NRDL update added 114 drugs, with a focus on oncology, rare diseases, and chronic conditions.  

In parallel, the commercial insurance innovation drug catalogue includes 19 high-cost therapies, including five CAR-T therapies. This provides an additional pathway for products that may face pricing constraints in public systems.  

It is important to note that inclusion in the commercial insurance catalogue does not guarantee reimbursement but supports the development of multi-level healthcare financing. 

Even after reimbursement inclusion, hospital listing, procurement participation, and regional implementation remain critical steps before products reach patients. 

Procurement Reform Is Creating More Room for Device Innovation 

For medical devices, centralized procurement remains highly relevant. However, recent reforms point to a more differentiated approach. 

The introduction of an “innovation protection period” and price preferences for high-performance devices with clear clinical value suggests that procurement policy is beginning to distinguish clinically meaningful innovation from products competing mainly on price. 

How Foreign Manufacturers Should Align with China’s Healthcare Strategy 

For overseas manufacturers, the “15th Five-Year Plan” reinforces the need for proactive and integrated China strategies.  

Policy support is increasingly linked to:  

• Early regulatory alignment 
• Clear clinical value 
• Readiness for post-market compliance 

Companies that engage late or treat these elements separately are more likely to face delays or limited market access.  

Reassess China Registration Pathways at the Portfolio Level 

Expanded use of priority review pathways, acceptance of international clinical data, and selective use of real-world evidence require earlier and more structured pathway evaluation. 

Manufactures should access at the portfolio level: 

• Eligibility for priority or accelerated review 
• Use of international multi-regional clinical trial (MRCT) data 
• Opportunities to leverage real-world evidence where accepted 
• Suitability for optimized or expedited review pathways 

Important Note: Accelerated or flexible pathways remain conditional and product-specific, particularly for clinically urgent or high-value products.  

Embed China Regulatory Considerations Earlier in Global Development 

China regulatory requirements should be considered earlier in global development programs, particular for: 

• Product design and technical specifications 
• Clinical trial design and endpoint selection 
• Evidence generation strategy 

Integrating China requirements at an early stage reduces rework, supports smoother review, and improves alignment with downstream market access requirements. 

Strengthen Lifecycle Compliance and Inspection Readiness 

Faster approval pathways are increasingly accompanied by closer post-market oversight. Overseas Marketing Authorization Holders (MAHs) should ensure that quality, safety, and reporting systems remain fully China-compliant throughout the product lifecycle. 

Key priorities include: 

• China-compliant pharmacovigilance and adverse event reporting 
• Inspection-ready quality management systems 
• Preparedness for remote or off-site regulatory inspections 

Lifecycle compliance is becoming a key condition for maintaining regulatory flexibility and long-term market access.  

Link Registration Strategy with Reimbursement & Distribution Planning 

Registration decisions increasingly shape downstream market access.  

NRDL inclusion, commercial insurance coverage, hospital listing, centralized procurement, and private healthcare channels should be evaluated as part of a single strategy, not separate steps. 

Manufacturers should coordinate regulatory and commercial planning to: 

• Anticipate pricing and reimbursement expectations 
• Plan hospital listing and supply timelines 
• Align regulatory, pricing and market access strategies 

The emerging private insurance route may become especially relevant for high-value therapies that face constraints under public reimbursement or procurement systems. 

Final Thoughts 

China’s “15th Five-Year Plan” sends a consistent message: innovation remains central but must translate into real-world impact. 

For pharmaceutical and medical device companies, this means aligning innovation with clinical value, pricing expectations, reimbursement pathways, and healthcare system needs. 

Companies that integrate regulatory strategy, evidence generation, market access planning, and lifecycle compliance early will be better positioned to succeed in the evolving China market. 

For tailored support with China medical device registration, pharmaceutical regulatory pathways, NMPA strategy, or market access planning, contact Cisema to discuss your product and next steps. 

Further Information 

• Learn more about Cisema’s China medical device registration services, including NMPA submission strategy and lifecycle support 
• Explore our biopharmaceutical regulatory services in China, covering support in clinical development, regulatory strategy and registration pathways, quality and compliance management, and market access strategies 
• Track recent trends and approvals through Cisema’s China medical device approval tracker, which monitors class II and III medical device registrations 

References

• 121 Generic Drug Names Pass Formal Review for Commercial Insurance Innovative Drug Catalogue — China Economic Net‍
• 2025 National Reimbursement and Commercial Insurance Dual Catalogue Released — 114 New Drugs Added, Including 50 Innovative Drugs — State Council of the People's Republic of China‍
• Announcement on Further Optimizing the Review and Approval of Clinically Urgently Needed Overseas-Approved Drugs (No. 3 of 2026) — National Medical Products Administration‍
• Announcement of the National Medical Products Administration on Issuing the Working Procedures for Review and Approval of Conditional Drug MarketingAuthorization (No. 41, 2026) — National Medical Products Administration‍
• Central Meeting Emphasizes Support for Medical Device Development — Media Report — Medworld器械世界
• ‍China to Improve Drug Price Formation Mechanism for Reasonable Pricing — National Medical Products Administration
• ‍General Office of the State Council Issues Notice on Measures to Accelerate the Establishment of a Tiered Diagnosis and Treatment System — National Health Commission
• ‍Notice on Issuing Three Recommended Health Industry Standards, Including Hypertension Management Standards for Primary Healthcare Institutions — National Health Commission of the People's Republic of China
• ‍Outline of the 15th Five-Year Plan for National Economic and Social Development of the People's Republic of China — State Council of the People's Republic of China
• ‍Recommendations of the CPC Central Committee on Formulating the 15th Five-Year Plan for National Economic and Social Development (2026–2030) — Full Text Release and Healthcare Summary — MedTrend医趋势
• ‍Sixth Batch of National Volume-Based Procurement for High-Value Medical Consumables Opens — Rules Further Optimized, Mainstream Clinical Products Selected — National Healthcare Security Administration